Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

Genetic information submitted by millions of 23andMe users is now in the hands of pharmaceutical giant Regeneron, following a ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

Regeneron Pharmaceuticals said in a press release yesterday that it would acquire 23andMe’s Personal Genome Service (PGS), ...

The US’s credit rating took a hit on Friday, after Moody’s downgraded the country’s AAA rating. And then yesterday, bond ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Your DNA results are in — and they're 100% the property of a pharmaceutical manufacturer. It was announced today that 23andMe ...

The DNA testing firm 23andMe says it has entered into an agreement to be acquired by Regeneron Pharmaceuticals for $256m ...

Regeneron Pharmaceuticals has agreed to buy 23andMe for $256 million and plans to continue consumer DNA testing services without interruption.

Regeneron is acquiring “substantially all” of 23andMe’s assets for $256 million following a bankruptcy auction.